Lexicon Pharmaceutcl (LXRX) Stock Price, Quote & News

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 863 3000

Fax: 281 863 8088

Website: www.lexpharma.com

Address:

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

beezee8 Feb. 25 at 1:21 PM

$LXRX Ray has been a busy boy - numerous catalysts coming up this year, but personally I feel that Zynquista is the one he is hanging his hat on

0 · Reply

Anon_ymous1 Feb. 25 at 12:59 PM

$LXRX Debanne strikes again, how about a new sec everyday this week, maybe include next week too while at it

0 · Reply

SniperPro Feb. 25 at 12:59 PM

$LXRX Breaking News: LXRX Chairman Ray, in a stunning display of brilliance, has found his own marbles and decided to personally splurge on 1.9 million shares. Oh, but wait... there's more...

0 · Reply

SocioCobb Feb. 25 at 12:54 PM

$LXRX I'm late posting this. 👍

0 · Reply

Kocatka Feb. 25 at 12:42 PM

$LXRX Vikings are coming

0 · Reply

Onedaytolive Feb. 25 at 12:28 PM

$LXRX This insider is definitely buying too many shares day after day, isn't he? I assume he's using dollar-cost averaging, but the stock price has already reached $1.50. Not long ago, you could buy a lot for just 30 cents...

1 · Reply

AZOZ Feb. 25 at 12:14 PM

$LXRX Insider activity!

1 · Reply

CharlyBue Feb. 25 at 12:12 PM

$LXRX what‘s up https://lexiconpharma.gcs-web.com/node/16761/html

0 · Reply

beezee8 Feb. 25 at 12:11 PM

$LXRX Another 100k purchase by RD on Monday. https://lexiconpharma.gcs-web.com/node/16761/html

1 · Reply

atreus57 Feb. 25 at 12:02 PM

$LXRX The conservative estimation is $7, but it can easily reach $10-$11 soon

0 · Reply

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Jan 30, 2026, 2:50 AM EST - 26 days ago

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Jan 29, 2026, 4:31 PM EST - 26 days ago

Lexicon Announces Proposed Public Offering of Common Stock

Jan 23, 2026, 8:30 AM EST - 4 weeks ago

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

Jan 21, 2026, 8:30 AM EST - 5 weeks ago

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

Jan 20, 2026, 6:59 AM EST - 5 weeks ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

VTRS

Jan 15, 2026, 5:26 PM EST - 5 weeks ago

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:30 AM EST - 6 weeks ago

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 8:30 AM EST - 6 weeks ago

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

Jan 7, 2026, 8:30 AM EST - 7 weeks ago

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 10, 2025, 8:30 AM EST - 2 months ago

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Dec 5, 2025, 8:30 AM EST - 2 months ago

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Dec 3, 2025, 10:30 AM EST - 2 months ago

Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well

Nov 25, 2025, 8:30 AM EST - 3 months ago

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Nov 19, 2025, 3:53 PM EST - 3 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 15, 2025, 6:46 AM EST - 3 months ago

Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win

Nov 11, 2025, 8:30 AM EST - 3 months ago

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Nov 8, 2025, 2:30 PM EST - 3 months ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Nov 6, 2025, 2:16 PM EST - 3 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:30 AM EST - 3 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Nov 4, 2025, 8:30 AM EST - 4 months ago

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Oct 30, 2025, 8:30 AM EDT - 4 months ago

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Oct 8, 2025, 7:59 AM EDT - 5 months ago

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Sep 22, 2025, 4:00 PM EDT - 5 months ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 17, 2025, 7:00 AM EDT - 5 months ago

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Sep 11, 2025, 8:30 AM EDT - 5 months ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Sep 8, 2025, 8:30 AM EDT - 6 months ago

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 4, 2025, 8:30 AM EDT - 6 months ago

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Sep 3, 2025, 7:36 PM EDT - 6 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 8:30 AM EDT - 6 months ago

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Sep 2, 2025, 8:30 AM EDT - 6 months ago

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Aug 27, 2025, 8:30 AM EDT - 6 months ago

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Aug 6, 2025, 12:39 PM EDT - 7 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:30 AM EDT - 7 months ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:00 AM EDT - 7 months ago

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 23, 2025, 8:00 AM EDT - 7 months ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 18, 2025, 8:00 AM EDT - 7 months ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Jun 23, 2025, 8:00 AM EDT - 8 months ago

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 8:30 AM EDT - 9 months ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

May 29, 2025, 8:00 AM EDT - 9 months ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 10 months ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 13, 2025, 9:47 PM EDT - 10 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:00 PM EDT - 10 months ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 10 months ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 10 months ago

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 25, 2025, 9:00 AM EDT - 10 months ago

Top 2 Health Care Stocks That May Crash This Month

Apr 2, 2025, 8:00 AM EDT - 11 months ago

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 28, 2025, 10:09 AM EDT - 11 months ago

Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal

NVO

Mar 28, 2025, 9:02 AM EDT - 11 months ago

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk

NVO

beezee8 Feb. 25 at 1:21 PM

$LXRX Ray has been a busy boy - numerous catalysts coming up this year, but personally I feel that Zynquista is the one he is hanging his hat on

0 · Reply

Anon_ymous1 Feb. 25 at 12:59 PM

$LXRX Debanne strikes again, how about a new sec everyday this week, maybe include next week too while at it

0 · Reply

SniperPro Feb. 25 at 12:59 PM

$LXRX Breaking News: LXRX Chairman Ray, in a stunning display of brilliance, has found his own marbles and decided to personally splurge on 1.9 million shares. Oh, but wait... there's more...

0 · Reply

SocioCobb Feb. 25 at 12:54 PM

$LXRX I'm late posting this. 👍

0 · Reply

Kocatka Feb. 25 at 12:42 PM

$LXRX Vikings are coming

0 · Reply

Onedaytolive Feb. 25 at 12:28 PM

1 · Reply

AZOZ Feb. 25 at 12:14 PM

$LXRX Insider activity!

1 · Reply

CharlyBue Feb. 25 at 12:12 PM

$LXRX what‘s up https://lexiconpharma.gcs-web.com/node/16761/html

0 · Reply

beezee8 Feb. 25 at 12:11 PM

$LXRX Another 100k purchase by RD on Monday. https://lexiconpharma.gcs-web.com/node/16761/html

1 · Reply

atreus57 Feb. 25 at 12:02 PM

$LXRX The conservative estimation is $7, but it can easily reach $10-$11 soon

0 · Reply

Kocatka Feb. 24 at 10:12 PM

$LXRX Charles Schwab has Earnings Call expected MARCH 5TH before market open. This has not been confirmed by Lexicon. #1 Most Important update to Steno Exposure Timing, has this been satisfied for the FDA. If not how many more weeks ETA. #2 Partnership Decisions Update for both LX9211 and Sotsgliflozin.

2 · Reply

Anon_ymous1 Feb. 24 at 9:37 PM

$LXRX Thought it was a late reaction to the insider buys but then all the progress got wiped out.

0 · Reply

Daywalker777 Feb. 24 at 9:30 PM

$LXRX how did we go from $1.62 down to red zone on a surging Green Day ?? So sad. We do need to have our day similar to IBRX which was disappointing for a long time before it went up from two dollars! It bought me some time to wait for LXRX. 😭

1 · Reply

UofMAlum Feb. 24 at 9:15 PM

$LXRX well, that was disappointing...

0 · Reply

selftaught Feb. 24 at 8:59 PM

$LXRX dang there it goes. waiting for the pullback. False breakout. I thought yesterday was the false breakout but looks like it was today.

0 · Reply

KurwaMac Feb. 24 at 7:21 PM

$LXRX we need some IBRX moves here

0 · Reply

UofMAlum Feb. 24 at 6:52 PM

$LXRX

0 · Reply

KurwaMac Feb. 24 at 5:33 PM

$LXRX

0 · Reply

copper2millies Feb. 24 at 4:36 PM

$LXRX Guys... Everyone realizes we are up $0.03 today (about 2%), right? If someone was just looking at these comments, they would think the stock is exploding.

4 · Reply

Hit1000X Feb. 24 at 4:31 PM

$LXRX

1 · Reply

atreus57 Feb. 24 at 3:50 PM

$LXRX my forecast stands: above $7 by November... I expect much more, above $10 maybe, but $7 remains the most conservative estimate...

1 · Reply

LionNoRichy Feb. 24 at 3:46 PM

$LXRX I wanna see $1.8 first, then TO

1 · Reply

Market Cap	548.83M
Revenue (ttm)	31.08M
Net Income (ttm)	-200.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-644.79%
Debt to Equity Ratio	0.47

Volume	2,535,200
Avg Vol	2,682,148
Day's Range	N/A - N/A
Shares Out	363.47M
Stochastic %K	59%
Beta	0.98
Analysts	Sell
Price Target	$2.92